| dbo:abstract |
Empagliflozin/linagliptin, sold under the brand name Glyxambi, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes. It is a combination of empagliflozin and linagliptin. It is taken by mouth. The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections . It was approved for use in the United States in January 2015, for use in the European Union in November 2016, and for use in Australia in December 2016. (en) |
| dbo:alternativeName |
Glyxambi (en) |
| dbo:casNumber |
668270-12-0 864070-44-0 |
| dbo:fdaUniiCode |
3X29ZEJ4R2 HDC1R2M35U |
| dbo:kegg |
D10588 |
| dbo:pubchem |
85364159 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Empagliflozin.svg?width=300 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/name/empagliflozin%20mixture%20with%20linagliptin |
| dbo:wikiPageID |
45292761 (xsd:integer) |
| dbo:wikiPageLength |
9343 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
996939063 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Boehringer_Ingelheim dbr:Oral_administration dbr:Eli_Lilly_and_Company dbr:Empagliflozin dbr:Anti-diabetic_medication dbr:Linagliptin dbr:Combination_drug dbc:Anti-diabetic_drugs dbr:Type_2_diabetes dbc:Boehringer_Ingelheim dbc:Combination_drugs dbc:Eli_Lilly_and_Company_brands dbr:SGLT2_inhibitor dbr:DPP-4_inhibitor |
| dbp:atcPrefix |
A10 (en) |
| dbp:atcSuffix |
BD19 (en) |
| dbp:c |
48 (xsd:integer) |
| dbp:casNumber |
668270 (xsd:integer) 864070 (xsd:integer) |
| dbp:cl |
1 (xsd:integer) |
| dbp:class |
dbr:SGLT2_inhibitor dbr:DPP-4_inhibitor |
| dbp:component |
Empagliflozin (en) Linagliptin (en) |
| dbp:dailymedid |
Glyxambi (en) |
| dbp:h |
55 (xsd:integer) |
| dbp:image |
Linagliptin.png (en) |
| dbp:kegg |
D10588 (en) |
| dbp:legalEu |
Rx-only (en) |
| dbp:legalStatus |
Rx-only (en) |
| dbp:legalUk |
POM (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:licenceEu |
yes (en) |
| dbp:licenceUs |
Glyxambi (en) |
| dbp:n |
8 (xsd:integer) |
| dbp:o |
9 (xsd:integer) |
| dbp:pregnancyAu |
D (en) |
| dbp:pregnancyUs |
N (en) |
| dbp:pubchem |
85364159 (xsd:integer) |
| dbp:routesOfAdministration |
dbr:Oral_administration |
| dbp:smiles |
CC#CCN1C2=CNC.COC1CO (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
POMOOZUJAXCEKG-QPVQWCQSSA-N (en) |
| dbp:tradename |
Glyxambi (en) |
| dbp:type |
combo (en) |
| dbp:unii |
3 (xsd:integer) HDC1R2M35U (en) |
| dbp:verifiedrevid |
448787104 (xsd:integer) |
| dbp:width |
180 (xsd:integer) 200 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Gastrointestinal-drug-stub dbt:Cite_journal dbt:Cite_web dbt:Drugbox dbt:Portal_bar dbt:Reflist dbt:Use_dmy_dates dbt:Cascite dbt:Fdacite dbt:Keggcite dbt:Oral_hypoglycemics_and_insulin_analogs dbt:Drugs.com dbt:Eli_Lilly_and_Company |
| dcterms:subject |
dbc:Anti-diabetic_drugs dbc:Boehringer_Ingelheim dbc:Combination_drugs dbc:Eli_Lilly_and_Company_brands |
| gold:hypernym |
dbr:Combination |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:CombinationDrug dbo:Drug |
| rdfs:comment |
Empagliflozin/linagliptin, sold under the brand name Glyxambi, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes. It is a combination of empagliflozin and linagliptin. It is taken by mouth. The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections . It was approved for use in the United States in January 2015, for use in the European Union in November 2016, and for use in Australia in December 2016. (en) |
| rdfs:label |
Empagliflozin/linagliptin (en) |
| owl:sameAs |
freebase:Empagliflozin/linagliptin yago-res:Empagliflozin/linagliptin wikidata:Empagliflozin/linagliptin https://global.dbpedia.org/id/uBXS |
| prov:wasDerivedFrom |
wikipedia-en:Empagliflozin/linagliptin?oldid=996939063&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Empagliflozin.svg wiki-commons:Special:FilePath/Linagliptin.png |
| foaf:isPrimaryTopicOf |
wikipedia-en:Empagliflozin/linagliptin |
| is dbo:wikiPageRedirects of |
dbr:Empagliflozin;_linagliptin dbr:Glyxambi dbr:Linagliptin/empagliflozin |
| is dbo:wikiPageWikiLink of |
dbr:Empagliflozin dbr:Linagliptin dbr:ATC_code_A10 dbr:Empagliflozin;_linagliptin dbr:Glyxambi dbr:Linagliptin/empagliflozin |
| is foaf:primaryTopic of |
wikipedia-en:Empagliflozin/linagliptin |
